Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
STR | Ann: mFund - Removal from Settlement Service - STR01 | 01/09/22 | 0 | 282 | |||
|
|||||||
STR | Ann: mFund - Fund Profile - STR01 | 16/08/22 | 0 | 216 | |||
|
|||||||
STR | Ann: mFund - Removal from Settlement Service - STR01 | 16/08/22 | 0 | 219 | |||
|
|||||||
STR | Ann: mFund - July 2022 Monthly Redemption Report - STR01 | 05/08/22 | 0 | 285 | |||
|
|||||||
STR | Ann: mFund - June 2022 Distribution - STR01 | 26/07/22 | 0 | 194 | |||
|
|||||||
STR | Ann: mFund - Monthly Redemption Report - STR01 | 05/07/22 | 0 | 221 | |||
|
|||||||
STR | Ann: mFund - May 22 Monthly Redemption Report - STR01 | 03/06/22 | 0 | 287 | |||
|
|||||||
STR | Ann: mFund - May 22 Monthly Redemption Report - STR01 | 05/05/22 | 0 | 233 | |||
|
See All Discussions